학술논문
Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035))
Document Type
Erratum
Author
Rondeau, E.; Scully, M.; Ariceta, G.; Barbour, T.; Cataland, S.; Heyne, N.; Miyakawa, Y.; Ortiz, S.; Swenson, E.; Vallee, M.; Yoon, S.-S.; Kavanagh, D.; Haller, H.; Babu, S.; Broeders, N.; Lietar, N.; Brown, F.; Campbell, P.; Campistol, J.M.; Blasco, M.; Chowdhury, P.; Kasimatis, T.; Cirami, L.; Caroti, L.; Antognoli, G.; Delmas, Y.; Dobronravov, V.; Gaeckler, A.; Garrouste, C.; Greenwood, G.; Griffin, S.; Huang, C.-C.; Chen, I.-R.; Huang, S.; Kim, J.S.; La Manna, G.; Comai, G.; Cappuccilli, M.; Le Quintrec, M.; Jeantet, G.; Fumie, I.; Luque, Y.; Menne, J.; Morelle, J.; Goffin, E.; Muhlfeld, A.; Nagaraj, S.; Arepally, G.; Oh, D.; Okumi, M.; Terente, M.P.; Gutierréz, E.; Rodriguez, P.; Provot, F.; Schönermarck, U.; Fischereder, M.; Terrada, N.R.; Seitz-Polski, B.; Favre, G.; Boyer-Suavet, S.; Vinogradova, M.; Kirsanova, T.; Wong, E.K.S.
Source
In: Kidney International . (Kidney International, May 2021, 99(5):1244)
Subject
Language
English
ISSN
15231755
00852538
00852538